A multi-center, double-blind, placebo-controlled, randomized, multiple dose, 2-period cross-over, Phase IIa study to investigate the pharmacodynamics, tolerability and safety, and pharmacokinetics of ACT 129968 in subjects with mild to moderate allergic asthma
Latest Information Update: 16 Sep 2015
At a glance
- Drugs Setipiprant (Primary)
- Indications Allergic asthma
- Focus Pharmacodynamics
- Sponsors Actelion Pharmaceuticals
- 23 May 2012 Results presented at the 108th International Conference of the American Thoracic Society.
- 06 Jul 2011 New trial record